Parameter
Mehr zum Buch
Pharmacoepidemiological databases are essential for effective quality improvements and targeted risk management of adverse drug effects. These retrospective databases enable investigations into specific subpopulations, such as those with particular diagnoses, due to their extensive size and observation duration. Research has shown that well-planned observational studies can yield results comparable to randomized controlled trials. This volume presents eight epidemiological and health-economic studies derived from two significant databases: the IMS Disease Analyzer and IMS LRx. The IMS® Disease Analyzer is one of Europe’s most comprehensive pharmacoepidemiological databases, underpinning numerous studies and peer-reviewed publications in various fields, including pharmacoepidemiology, health economics, and drug safety. These studies analyze therapy duration, adverse effects, costs, and compliance, contributing significantly to drug safety and risk prevention. The IMS® LRx database encompasses nationwide pharmacy data, processing prescription data for nearly all German patients with statutory health insurance since 2008. This compilation of studies highlights the advantages of utilizing secondary data from retrospective databases to enhance everyday healthcare practices.
Buchkauf
Medical care in Germany, Karel Kostev
- Sprache
- Erscheinungsdatum
- 2011
Lieferung
Zahlungsmethoden
Keiner hat bisher bewertet.